Related references
Note: Only part of the references are listed.HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
T. Van Gorp et al.
BRITISH JOURNAL OF CANCER (2011)
A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer
Claire S. Zhu et al.
CANCER PREVENTION RESEARCH (2011)
Challenges Related to Developing Serum-Based Biomarkers for Early Ovarian Cancer Detection
Phuong L. Mai et al.
CANCER PREVENTION RESEARCH (2011)
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens
Daniel W. Cramer et al.
CANCER PREVENTION RESEARCH (2011)
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass
Richard G. Moore et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2010)
Phase II biomarker trial of a multimarker diagnostic for ovarian cancer
Tracey Edgell et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
HE4: a new potential early biomarker for the recurrence of ovarian cancer
Emanuela Anastasi et al.
TUMOR BIOLOGY (2010)
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2009)
Development and Preliminary Evaluation of a Multivariate Index Assay for Ovarian Cancer
Suraj D. Amonkar et al.
PLOS ONE (2009)
Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer
Greg P. Bertenshaw et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics: A Gynecologic oncology group study
Mark H. Greene et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Ovarian Cancer Early Detection Claims Are Biased
Martin McIntosh et al.
CLINICAL CANCER RESEARCH (2008)
Diagnostic markers for early detection of ovarian cancer
Irene Visintin et al.
CLINICAL CANCER RESEARCH (2008)
Diagnostic Markers for Ovarian Cancer Screening: Not Ready for Routine Clinical Use
Ralph J. Coates et al.
CLINICAL CANCER RESEARCH (2008)
Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples
Kristin Skogstrand et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers
Jason D. Thorpe et al.
PLOS ONE (2007)
Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125
Ben Van Calster et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Plasma tissue inhibitor of metalloproteinases-1 as a biological marker?: Pre-analytical considerations
Anne F. Lomholt et al.
CLINICA CHIMICA ACTA (2007)
Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: A multicenter study by the International Ovarian Tumor Analysis Group
D Timmerman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer
E Gorelik et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions
SJ Skates et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cancer antigen 125 associated with multiple benign and malignant pathologies
C Miralles et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Use of proteomic patterns in serum to identify ovarian cancer
EF Petricoin et al.
LANCET (2002)
Share Paper
